Description Module

Description Module

The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.

Description Module path is as follows:

Study -> Protocol Section -> Description Module

Description Module


Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2025-12-25 @ 3:29 AM
NCT ID: NCT02794805
Brief Summary: An Octanoate breath test will be used to assess the presence of Hepatocellular Carcinoma in subjects with risk. The gold standard will be MRI.
Detailed Description: 1. Informed consent will be obtained from all patients prior to enrollment. 2. The trial will be conducted in compliance with this protocol, with GCP standards, and the applicable regulatory requirements. 3. This study will be cross-sectional, where patients will be enrolled on a walk in basis. Once one arm is completed the other one will be enriched in order to obtain at least 50 positive and at least 50 negative HCC subjects as defined by MRI. 4. All patients will undergo AFP and US if they do not have results within the past three months. 5. If the patient undergoes liver FNA, the biopsy results will be evaluated for the presence of HCC. 6. For all patients, a case report form will be completed. 7. All patients will undergo a physical examination, and their medical history/concomitant medications, weight, height and age will be recorded. Furthermore, recent (past 3 months) blood test results, if available, may be recorded. 8. If relevant (woman of child bearing age), a pregnancy test will be performed to rule out pregnancy when performing the breath test. 9. All MRI negative patients with low OBT results will undergo additional MRI within 6 to 12 months post OBT to rule out HCC occurrence. 10. If available, all additional MRI/CT/US results will be recorded within the patient's CRF.
Study: NCT02794805
Study Brief:
Protocol Section: NCT02794805